COX-2 expression in pseudomyxoma peritonei.
COX-2 expression was studied using an immunohistochemical method in 75 patients with pseudomyxoma peritonei (PMP). Twenty-five patients presented with disseminated peritoneal adenomucinosis (DPAM) and 50 with peritoneal mucinous carcinomatosis (PMCA). COX-2 was expressed in neoplastic mucinous epithelium of 30 cases (40%): 20 in PMCA (40%), 10 in DPAM (40%). Weak COX-2 expression was also noted in four of five patients with appendiceal mucinous neoplasms without peritoneal dissemination. In addition, COX-2 was detected in stromal, endothelial, inflammatory cells and reactive mesothelium. This preliminary information indicates a potential for the use of COX-2 inhibitors in patients with PMP.
Gatalica
Zoran
Z
Department of Pathology, Creighton University Medical Center, 601 N 30th Street, Omaha, NE 68131, USA. zgatalica@pathology.creigton.edu
Loggie
Brian
B
D002288:Adenocarcinoma, Mucinous / Q000175:diagnosis / Q000201:enzymology / Q000556:secondary; D000328:Adult; D000368:Aged; D001063:Appendiceal Neoplasms / Q000175:diagnosis / Q000201:enzymology / Q000556:secondary; D051546:Cyclooxygenase 2 / Q000378:metabolism*; D018291:Cystadenoma, Mucinous / Q000175:diagnosis / Q000201:enzymology / Q000556:secondary; D042783:Endothelial Cells / Q000201:enzymology / Q000473:pathology; D004848:Epithelium / Q000201:enzymology / Q000473:pathology; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D008297:Male; D008565:Membrane Proteins / Q000378:metabolism*; D008875:Middle Aged; D010534:Peritoneal Neoplasms / Q000175:diagnosis / Q000201:enzymology* / Q000556:secondary; D011379:Prognosis; D011446:Prospective Studies; D011553:Pseudomyxoma Peritonei / Q000150:complications / Q000175:diagnosis / Q000201:enzymology*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D017154:Stromal Cells / Q000201:enzymology / Q000473:pathology
D051546:Cyclooxygenase 2; D008565:Membrane Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases; C496540:PTGS2 protein, human